In the abstract of the original article, there is a duplicate description of “We have successfully fabricated versatile folate-targeted and oxygen/indocyanine green-loaded lipid nanoparticles (FA-OINPs) for dual-mode imaging-guided therapy in ovarian cancer cells and subcutaneous xenograft models. FA-OINPs were demonstrated to have great potential as superb contrast agents to enhance ultrasound and photoacoustic (US/PA) imaging. We have successfully fabricated versatile folate-targeted and oxygen/indocyanine green-loaded lipid nanoparticles (FAOINPs) for dual-mode imaging-guided therapy in ovarian cancer cells and subcutaneous xenograft models. FA-OINPs were demonstrated to have great potential as superb contrast agents to enhance ultrasound and photoacoustic (US/PA) imaging in vitro and in vivo.” The correct abstract is given below, “We have successfully fabricated versatile folate-targeted and oxygen/indocyanine green-loaded lipid nanoparticles (FAOINPs) for dual-mode imaging-guided therapy in ovarian cancer cells and subcutaneous xenograft models. FA-OINPs were demonstrated to have great potential as superb contrast agents to enhance ultrasound and photoacoustic (US/PA) imaging in vitro and in vivo. Confocal laser scanning microscopy and flow cytometry analysis verified that FA-OINPs could specifically target SKOV3 ovarian cancer cells and be endocytosed with remarkable efficiency. Compared with other therapeutic options, FA-OINPs exhibited an excellent therapeutic outcome after exposure to laser and ultrasound. The MTT assay and flow cytometry analysis confirmed that cytotoxicity effects and apoptosis/necrosis rates were significantly increased. The fluorescence microscopy and fluorescence microplate reader detection validated that the generation of intracellular reactive oxygen species (ROS) was dramatically improved. Immunohistochemical analyses of tumor tissues demonstrated the enhanced tumor apoptosis, the decreased vascular endothelial growth factor (VEGF) and microvascular density (MVD) expression, and the decreased expression of CD68 after treatment. The presented results suggest that photo-sonodynamic/photothermal mediated FA-OINPs could provide a promising strategy for synergistic therapy in ovarian cancer with the guidance of US/PA dual-mode imaging.” Y.L. and S.C. are co-first authors who have contributed equally to this work. This article has not yet been cited by other publications.

中文翻译：

---

叶酸靶向和氧/吲哚菁绿负载脂质纳米颗粒，用于体外和体内双模式成像和光声动力学/光热疗法治疗卵巢癌。

在原始文章的摘要中，存在重复的描述：“我们已经成功地制造了多用途叶酸靶向和氧/吲哚菁绿负载脂质纳米粒（FA-OINPs），用于卵巢癌细胞和肿瘤细胞的双模式成像引导治疗。皮下异种移植模型。事实证明，FA-OINP作为超强对比剂具有巨大的潜力，可以增强超声和光声（US / PA）成像。我们已经成功地制造了多用途叶酸靶向和氧/吲哚菁绿负载脂质纳米颗粒（FAOINPs），用于卵巢癌细胞和皮下异种移植模型的双模式成像引导疗法。事实证明，FA-OINP具有极好的潜力，可作为出色的造影剂，在体外和体内增强超声和光声（US / PA）成像。” 正确的摘要如下，“我们已经成功地制备了多种靶向叶酸和负载氧/吲哚菁绿的脂质纳米颗粒（FAOINP），用于卵巢癌细胞和皮下异种移植模型的双模式成像指导治疗。事实证明，FA-OINPs作为极好的造影剂具有巨大的潜力，可以在体外和体内增强超声和光声（US / PA）成像。共聚焦激光扫描显微镜和流式细胞术分析证实，FA-OINPs可以特异性靶向SKOV3卵巢癌细胞，并以显着的效率被内吞。与其他治疗选择相比，FA-OINP在暴露于​​激光和超声后表现出出色的治疗效果。MTT测定法和流式细胞术分析证实，细胞毒性作用和凋亡/坏死率显着增加。荧光显微镜和荧光酶标仪的检测验证了细胞内活性氧（ROS）的产生得到了显着改善。肿瘤组织的免疫组织化学分析显示，治疗后肿瘤细胞凋亡增强，血管内皮生长因子（VEGF）和微血管密度（MVD）表达降低，CD68表达降低。提出的结果表明，在US / PA双模成像的指导下，光声动力学/光热介导的FA-OINP可以为卵巢癌的协同治疗提供有希望的策略。” YL和SC是共同致力于该工作的第一作者。本文尚未被其他出版物引用。